Latest News for INCR
NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company's closing bid price for its ordinary shares, or…
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year.
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA.
InterCure Ltd. (NASDAQ: INCR - Get Free Report)'s stock price fell 6.6% during trading on Tuesday. The stock traded as low as $0.9895 and last traded at $0.99. 537,181 shares traded hands during mid-day trading, an increase of 833% from the average session volume of 57,585 shares. The stock had previously closed at $1.06. Wall
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INCR.
U.S. House Trading
No House trades found for INCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.